DUPIXENT 300 mg group (n=72) and placebo group (n=37), respectively: mean ages 51 ± 13 and 49 ± 12 years; 64% and 59% female; mean FeNO 63 ppb ± 40 and 53 ppb ± 25; mucus plug score 7.2 ± 5.1 and 6.9 ± 5.0; pre-bronchodilator FEV1 1900 mL ± 700 mL and 1900 mL ± 700 mL.
Background therapy: medium-to-high dose ICS + second controller ± third controller
dCT scans.5
Primary endpoints: Proportion of patients achieving FeNO <25 ppb at Week 24, and percent change from baseline to Week 24 in (s)iVaw at TLC.5
Select secondary and other endpoints: Change from baseline in pre-bronchodilator FEV1 at Week 24, and change from baseline in mucus plug score at Week 24 and CT scans of mucus plug volume (exploratory).5
The primary imaging endpoint ([s]iVaw at TLC) did not reach statistical significance (P>0.05); therefore all subsequent endpoints are descriptive; definitive conclusions cannot be made.5
What is functional respiratory imaging (FRI)?
ACQ-5, Asthma Control Questionnaire, 5-item version; CT, computed tomography; EOS, eosinophil; EOT, end of treatment; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; OLE, open-label extension; Q2W, once every 2 weeks; (s)iVaw, specific image-based airway volume; TLC, total lung capacity.